title: A long war begins: biosimilars versus patented biologics.
authors.affiliation: a Faculty of Pharmacy , Paris Descartes University, Sorbonne Paris Cité, Paris, France, Health Law Institute, Inserm, UMR S 1145, Paris Descartes University, Sorbonne Paris Cité, Paris, France, and General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) , Paris , France.
authors.forename: François
authors.initials: F
authors.lastname: Bocquet
authors.affiliation: a Faculty of Pharmacy , Paris Descartes University, Sorbonne Paris Cité, Paris, France, Health Law Institute, Inserm, UMR S 1145, Paris Descartes University, Sorbonne Paris Cité, Paris, France, and General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) , Paris , France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Paubel
mesh_terms: D001688:Biological Products / Q000191:economics / Q000592:standards; D059451:Biosimilar Pharmaceuticals / Q000191:economics / Q000592:standards*; D017046:Cost Savings / Q000379:methods; D006801:Humans
chemical_list: D001688:Biological Products; D059451:Biosimilar Pharmaceuticals
keywords: Biologics; Granulocyte-Colony Stimulating Factor; biosimilars; epoetin; generics; monoclonal antibodies.